contemporary recommendations for diagnosis and management of lower extremity PAD [2] . However, these documents did not address the selection of specific devices when EVT is indicated. Device choices for EVT in the FP arterial bed remain challenging due to a wide spectrum of available endovascular device options and a paucity of comparative effectiveness data. The purpose of this first device-focused consensus document is to provide a review of comparative effectiveness data, including safety and efficacy of FP devices, and to provide clinicians with guidance and recommendations for device selection, when these devices are intended as the definitive or adjunctive therapy.
| M E TH ODOL OGY
This document provides recommendations applicable to devices used for EVT in FP disease. The goal is to guide clinical judgment with an emphasis on evidence-based and cost-effective utilization. This document is intended as a guide to improve decision making regarding EVT device selection for patients undergoing EVT.
A balanced writing group was nominated and selected based on their EVT expertise, with consideration of relationships with industry and professional specialty or area of focus. The Writing Group Chairman and 50% of the members had no relevant relationships with industry ( Table 1) . The recommendations listed, whenever possible, were based on randomized controlled trials (RCTs) and meta-analyses, but also included registries, nonrandomized comparative studies, case series, cohort studies, and expert opinion. The writing committee chose the studies to highlight in this document; the final summary of the reviewed and most relevant clinical data is included in the Supporting Information Tables S1-S7.
The Class (strength) of Recommendation (COR) represents the anticipated magnitude and certainty of comparative benefit for a group of devices (i.e., symptom improvement, patency, functional status, and/ or quality of life) against the risks and cost of the device use based on the SCAI (modified ACC/AHA guideline recommendation) [3] classification ( Table 2 ). The Level of Evidence (LOE) provides evidence supporting the effect of the devices on the basis of the type, quality, quantity, and consistency of data. The COR and LOE are determined independently; any COR may be paired with any LOE.
The committee used a modified Delphi panel methodology, which employed an expert panel of clinicians who rated a series of anatomical scenarios with respect to COR/LOE. The panel participated in three rounds of voting, with communication among the panelists after the first anonymized round. Each panelist had equal weight in determining the final rating. Agreement among panelists was achieved when >80% of the recommendations ratings for the scenarios were concordant (Tables 2 and 3 ).
| Definitions and assumptions
1. The scenarios chosen in this document are largely based on the anatomical features of the lesions and presence of hemodynamically significant FP disease rather than clinical presentation and are not intended to be all-inclusive.
2. Lesion length is categorized into focal (<10 cm), intermediate (10-20 cm) , and diffuse (>20 cm), which is consistent with the definitions used for the peripheral vascular interventions AUC document [1] .
3. For all device scenarios, assume that COR/LOE (Table 1) are provided for groups or categories of devices and not intended to compare individual devices and/or manufacturers. 4 . The COR/LOE for a category of the devices were assigned according to the best comparative evidence-based data from the published trials/registries, with conventional uncoated PTA frequently being the comparison group. For instance, Class III: No Benefit recommendation implies that there is no benefit relative to the comparison group (e.g., conventional uncoated balloon PTA), rather than no benefit at all from the examined category of the devices.
For device scenarios, this document focuses on the devices
intended as the definitive therapy (Table 3) , and not necessarily the final device therapy. PTA may be chosen as the intended definitive treatment, even if it may be necessary to use atherectomy for preparation of an undilatable lesion. DCB may be chosen as the intended definitive treatment with planned predilation with PTA. DCB or uncoated PTA may be chosen as the intended definitive treatment, even if it may be necessary to use "bail-out" stenting to preserve vessel patency.
6. The use of the adjunctive devices for lesion preparation, such as atherectomy or specialty balloons, is separately addressed in this document including recommendations for both dilatable and undilatable lesions (Table 4) . Atherectomy may be chosen as the adjunctive device for lesion preparation, whereas DCB may be selected as the intended definitive treatment.
7. The cost of the devices (Table 5) was considered secondary to examining efficacy and safety data when determining COR/LOE, particularly for devices with limited comparative clinical data that could justify their additional cost.
8. The utilization of a combination of different groups/categories of devices as the intended definitive therapy (e.g., laser atherectomy plus DCB for in stent restenosis) is not addressed and beyond the scope of this document.
9. Occlusion describes complete cessation of flow through the arterial segment.
10. Provisional stenting implies PTA with stent placement intended only for "bail-out" (i.e., for flow-limiting dissection or significant
[>50%] residual stenosis).
11. Primary stenting implies the intention to place a stent regardless of the outcome of any predilation or pretreatment.
| Clinical outcomes and endpoints, assessing the efficacy of revascularization
There has been a lack of consistent definitions and nomenclature across clinical trials of devices, drugs or biologics for the treatment of PAD. In an effort to overcome this barrier, the Peripheral Academic Research Consortium (PARC) developed consensus definitions for clinically
| 125 meaningful outcomes and endpoints [4] . The current consensus document recommends adopting the PARC definitions for acute procedural and technical success of EVT, short-and long-term surrogate endpoints of procedural success (using imaging and physiologic measures), and functional/clinical outcome definitions [4] . In patients with claudication, functional assessments using standardized validated treadmill protocols or 6-min hall walk testing should be used. In CLI patients, limb outcomes with respect to major and minor lower extremity amputation, wound healing, ischemic rest pain, and major adverse limb events (MALE) should be examined. In this document, when evaluating comparative effectiveness, clinical and functional outcomes (e.g., clinically driven TLR) were given greater emphasis than surrogate endpoints (e.g., DUSderived restenosis), which in turn were weighted more heavily than procedural success endpoints. When available, cost effectiveness studies were also taken into consideration in the recommendations.
| Anatomic, clinical, and technical definitions
Lower extremity PAD has classically been defined by the anatomic segments affected as aorto-iliac, femoral-popliteal (FP) segment, and below knee infra-popliteal (IP) or infrageniculate arteries. The FP segments represent the common femoral artery (CFA), profunda femoris artery (PFA), superficial femoral artery (SFA) and popliteal artery, the longest nonbranched vessel. In this document, we discuss devices specific to the above-knee FP segment, while separately addressing CFA disease.
The CFA bifurcation lesions refer to lesions that involve the common femoral bifurcation and ostial SFA/PFA; however, the recommendations also apply to isolated CFA disease. The above-knee popliteal artery segment includes the P1 (from intercondylar fossa to proximal edge of patella) and P2 (from proximal part of patella to center of knee joint space) popliteal segments. In addition to anatomical location, the lesions are classified according to length, stenosis versus occlusion, degree of calcification, and whether they represent de novo or in-stent restenosis (ISR). The TASC classification has previously placed FP lesions into 4 categories according to lesion length and whether disease is stenotic or occlusive [5] . However, in this document and relevant to existing data for devices in RCTs, we have defined lesion length as focal (<10 cm), intermediate (10-20 cm) , and diffuse (>20 cm), which is consistent with the AUC document [1] . 
| Common femoral artery EVT
Surgical endarterectomy has historically been the treatment of choice for CFA disease [7, 8] . However, recent reports of EVT (DCB, atherectomy, stenting) [9, 10] hospitalization with surgery (6.3 vs. 3.2 days, P < 0.0001); however, at 2 years there were no significant differences in freedom from TLR, patency or the sustained clinical improvement between the 2 groups.
Based on the single randomized trial and expert consensus, recommendations for EVT in CFA disease are listed in Table 3 .
| Uncoated balloons for percutaneous transluminal angioplasty
PTA therapy includes the use of conventional uncoated balloons. An "uncoated PTA-first" strategy that reserves stent placement for "bail-out" (Table 3) .
Recent meta-analyses of RCTs comparing treatment modalities in
FP disease demonstrated that PTA with uncoated balloons alone was inferior to bare metal stents, covered stents, DCB, and DES with respect to technical success, restenosis and TLR rates [13, 14] . For relatively short lesions (<5 cm), registry data suggested the primary patency rates approached 90% at 1 year, 80% at 2 years, and 70% at 3 years [15] . Comparative data from multiple RCTs of bare metal stents failed to demonstrate a benefit of stents over uncoated balloons PTA alone in lesions of <10 cm lengths [16, 17] . However, as lesion length increases (i.e., lesions >10 cm), data suggest superiority of bare metal stents over PTA with uncoated balloons alone [18, 19] .
Increasing amounts of FP lesion calcification increase the risk of PTA failure. Among 394 patients undergoing EVT for FP disease | 129 uncoated balloon PTA alone was successful in only 20% of cases, largely confined to noncalcified lesions [20] . In lesions with more severe calcification, the uncoated balloon PTA-only success rate was low, 8.3%. These data highlight the limitations of uncoated balloon PTA alone in severely calcified lesions.
Late patency rates following uncoated balloon PTA in CTOs at 12-36 months remain disappointing, with rates after a subintimal PTA approach declining from 70-80% at 6 months to 40-50% at 36 months [21, 22] . Restenosis rates with uncoated balloon PTA alone, particularly for long segments of ISR or occluded stents, have also been disappointing with restenosis and TLR rates approaching 50% [23, 24] .
Uncoated balloon PTA has demonstrated inferior outcomes when compared to DCB and laser atherectomy in ISR lesions [23, 25, 26] . Based on comparative clinical data, DCB or DES as the definitive device therapy for most lesions in the FP segment, with or without adjunctive PTA, would be preferred (Table 6 ). Table S1 ). There are no headto-head comparisons between different specialty balloons or newer technologies (e.g., DCB). All of the devices have demonstrated their safety, but have a substantially higher cost (Table 4) . In clinical practice, specialty balloons are rarely used as the intended definitive therapy but rather as the adjunctive, lesion preparation devices. Based on limited published data [27] [28] [29] [30] [31] [32] [33] , consensus recommendations for stand-alone specialty balloons utilization as the intended definitive therapy (Table   7) as well as the adjunctive (lesion preparation) therapy ( Table S2 ).
These studies were pooled in a 2014 Cochrane meta-analysis of 11
RCTs, enrolling 1,387 patients with claudication or CLI and TASC A or B lesions [37] . Collectively, these trials demonstrated superior 6-month patency by DUS and angiography, and superior 12-month patency by [45] . There was also a trend toward improved freedom from re-intervention among patients treated with a provisional DES strategy (84.9%) versus provisional BMS (71.6%).
Three single arm multicenter studies with predefined endpoints have further investigated the outcomes of Zilver PTX in real-world lesions: the Zilver PTX single arm study [46] [47] [48] , a Japanese postmarket surveillance study [49] , and the Japanese ZEPHYR registry [50] (Supporting Information Table S4 ). The Zilver PTX single arm study was a multinational registry of patients with symptomatic PAD treated with Zilver PTX [46] . The 12-month primary patency was 86.2%, and the 12-month freedom from TLR was 90.5%. The TASC C/D lesion subgroup of this registry included 135 lesions with a mean lesion length of 226 mm [47] . Twelve month primary patency was 77.6%, and 85.4%
freedom from TLR, with a stent fracture rate of only 2.1%. In the subgroup of 119 ISR lesions, primary patency was 78.8% at 1 year and freedom from TLR was 81% [48] (Table 10 ). Head to head clinical trials between the DCBs are needed to better understand their value relative to each other. Economic data have suggested DCB to be cost effective in the FP segment [52] [53] [54] . Among the current therapeutic options for FP disease, DCB receive strong recommendations based on the LOE from several RCTs. (Table 11) The 52.4%, 12 months, P < 0.001; 78.9% vs. 50.1%, 24 months, P < 0.001) [57, 58] . Likewise, DCB use was superior to uncoated PTA in terms of clinically driven TLR at 12 months, which also maintained at 24 months (DCB vs. PTA, 2.4% vs. 20.6%, 12 months, P < 0.001; 9.1% vs. 28.3%, 24 months, P < 0.001) [57, 58] .
| Drug coated balloons
The third DCB to achieve FDA approval for use in de novo and restenotic FP lesions was the Stellarex DCB resulting from the ILLUMENATE trial series [59] [60] [61] . [64, 65] . At 1 year, both recurrent restenosis and clinically driven TLR were favorable for DCB [64] . However, at 3 years, TLR rates were similar in DCB (40%) and PTA (43%) groups [65] .
Similarly, the FAIR (Femoral Artery In-Stent Restenosis) trial was a small, randomized, multicenter, German study evaluating DCB (n 5 62)
versus uncoated PTA (n 5 57) in patients with SFA ISR and CLI [23] .
Freedom from TLR was significantly better in the DCB cohort at 12 months (90.8% vs. 52.6%, P < 0.0001), though long-term results are not yet available.
| Covered (endovascular grafts) stents
The use of covered stents (Viabahn, W.L. Gore & Associates, Flagstaff, AZ) is FDA approved for treatment of FP disease. These stent grafts, covered with expanded polytetrafluoroethylene and a self-expanding versus BMS (71% vs. 55%, P 5 0.11) in complex FP lesions [66] . In long (20 cm) lesions, covered grafts had a significantly higher patency at 12 months (71% vs. 37%, P 5 0.01) [66] . At 24 months, Viabahn grafts had greater primary patency compared to BMS, however, without a significant impact on TLR rate [67] . In the VIBRANT trial, at 3 years, primary patency rates were not significantly different between patients treated with the VIABAHN graft and those who received BMS (24.2%
vs. 25.9%) [68] . In the single-arm VIPER (Viabahn Endoprosthesis with
Heparin Bioactive Surface in the Treatment of Superficial Femoral
Artery Obstructive Disease) study, primary patency at 12 months was 73%, which was not affected by device diameter (5 vs. 6 vs. 7 mm) or lesion length (20 cm vs. >20 cm) [69] . Similar findings were noted in a Japanese cohort, with 12-month primary patency not being affected by lesion length (93% in 20cm lesions versus 85% in >20 cm lesions,
The RELINE trial randomized patients with FP ISR to either PTA or PTA with Viabahn placement [71] . At 12 months the primary patency [72] . Stent thrombosis resulting in acute limb ischemia occurs more frequently following covered stent-grafts compared to BMS; covered stent oversizing, loss of collaterals and edge restenosis have been implicated as the contributing factors to stent graft failure [73] . The concerns regarding stent thrombosis and acute limb ischemia as the failure mode for covered stents have resulted in limited utilization of these devices as first-line definitive therapy for most de novo FP lesions (Table 12 ).
| Atherectomy
Atherectomy, the debulking by excision or ablation of atherosclerotic plaque, has been used in the FP segment, despite the lack of comparative outcomes data to justify the additional cost of these devices.
Numerous atherectomy devices have been developed over the last decade, including excisional and ablative devices (Supporting Information Table S7 ). There are no RCTs comparing atherectomy to stents (BMS or DES). It should be recognized that these devices are costly (Table 4 ) and are rarely used as a stand-alone definitive therapy, but rather as the adjunctive therapy for lesion preparation. Importantly, this document provides separate recommendations for atherectomy devices intended as the definitive therapy (Table 13 ) and recommendations for devices to be used for "adjunctive," lesion preparation purposes (Table 14) . Further data regarding adjunctive use of atherectomy devices, particularly in CFA, ostial SFA, and popliteal locations, are needed.
| Directional atherectomy
The feasibility of DA in the treatment of de novo FP disease was evaluated in the single arm registry, Determination of EFfectiveness of the SilverHawk PerIpheral Plaque ExcisioN System (SIlver-Hawk Device)
for the Treatment of InfrainguinalVEssels/LowerExtremities (DEFINI-TIVE LE) study [74] . This registry reported a 12-month primary patency of 78% in claudicants, with no difference between diabetics and nondiabetics. The use of DA was associated with a low use of stents 
| Excisional/aspiration atherectomy
There is no comparative evidence to support the use of the excisional/ aspiration atherectomy devices as a definitive treatment strategy. The largest peer-reviewed publication of the Pathway Atherectomy System (Boston Scientific, Inc., Marlborough, MA) included 172 patients at 9
European sites [78] . Lesions <10 cm in the FP and <3 cm in the infrapopliteal vessels with >70% stenosis were included. These lesions were rated to have moderate to high calcium scores in 50%. showed superior TLR, but later follow up was compromised by significant losses to follow up. Longer follow will be needed to support the use of this technology in ISR lesions. Another small trial (n 5 48) compared DCB 1 excimer LA to DCB alone in CLI patients with occlusion of the FP segment secondary to ISR. The patency rates at 12 months were significantly higher in the excimer LA 1 DCB group (66.7%) versus DCB alone (37.5%) [26] .
| Adjunctive therapies
A number of adjunctive therapies other than specialty balloons (discussed previously), such as brachytherapy, external beam radiation and cryoplasty have been tested in FP revascularization, which either lacked supportive data or failed to demonstrate significant advantages over currently available PTA and/or stents with respect to improving procedural success or future restenosis [82] [83] [84] . Novel therapies such as lithoplasty for calcified undilatable FP disease are currently being investigated [85] .
| Evidence gaps and future research directions
In developing these guidelines, the committee identified the following evidence gaps:
1. Consistent application and validation of definitions and classification systems (i.e., symptoms, anatomic features, plaque characteristics [e.g., extent of calcification], surrogate imaging endpoints, clinical outcomes) in EVT device trials is needed. The committee recommends adoption of the PARC definitions in future EVT trials.
2. Clinical trial processes should incorporate independent adjudication, and core laboratories for major endpoints and safety monitoring.
3. Randomized, prospective, comparative, protocol-driven device trials are needed to determine the value (clinical outcomes, patient safety, durability of treatment effect, and quality of life) and costeffectiveness of these devices in specific clinical circumstances and lesion subsets.
